EUVIMEDEUVIMED entdecken
Crossref

The N6-methyladenosine demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification

Yueheng Wang, Shengping He, Lan Lan, Hongjiao Yu, Huan Zhao, Yuchen Xie, Guoli Zhong, Liang Yuan, Kun Li, Xiao Hu, Vicky E Macrae, Xiaodong Fu und 2 weitere

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvae253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Yueheng Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second…. Hauptthemen laut MEDLINE: Aortic Valve, AlkB Homolog 5, RNA Demethylase, Epigenesis, Genetic, Adenosine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Science and Technology Projects of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Calcific aortic valve disease (CAVD) is a common heart valve disease with significant clinical consequences. The mechanisms that drive the pathogenesis of CAVD remain to be fully elucidated. N6-methyladenosine (m6A), the most prevalent RNA epigenetic regulator, has recently been implicated in cardiovascular disease, but its role in CAVD has yet to be investigated. In this study, we investigated the potential function of m6A modification in CAVD. Methods and results Using clinical samples from CAVD patients in combination with human valve interstitial cell (hVIC) calcification model, we screened the expression of m6A modulators and discovered that alkB homolog 5, RNA demethylase (ALKBH5), a key m6A demethylase, was significantly down-regulated in calcified hVICs and human aortic valves. Consistently, increased m6A levels were seen in calcified hVICs, and treatment with 3-deazaadenosine (DAA), an inhibitor of m6A modification, significantly reduced hVIC osteogenic differentiation and calcification. In addition, we showed that silencing of ALKBH5 expression increased global m6A levels and accelerated hVIC osteogenic differentiation and calcification, whereas overexpression of ALKBH5 resulted in the opposite effect. We demonstrated that ALKBH5 directly modulate m6A levels of TGFBR2 and its mRNA stability, leading to altered TGFBR2 expression and SMAD2 signalling in hVICs. We further showed that inhibition of TGFBR2 or knockdown of SMAD2 attenuated ALKBH5 knockdown-induced hVIC osteogenic differentiation and calcification. The expression of the m6A reader protein YTH N6-methyladenosine RNA binding protein F1 (YTHDF1) was up-regulated during the process of hVIC calcification. Intriguingly, we revealed that the ALKBH5 silencing-induced increased hVIC osteogenic differentiation and calcification were abolished after knockdown of YTHDF1. These data suggest a potential role YTHDF1 in aortic valve calcification.

Conclusion

This study showed that ALKBH5 attenuated aortic valve calcification through the TGFBR2/SMAD2 signalling pathway via direct m6A modification of TGFBR2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic ValveAlkB Homolog 5, RNA DemethylaseEpigenesis, GeneticAdenosineAortic Valve StenosisCalcinosisHeart Valve DiseasesHumansSignal TransductionCells, CulturedMaleOsteogenesisFemaleCell DifferentiationAgedMiddle AgedSmad2 Protein

Stichwörter der Autor:innen

ALKBH5Aortic valve calcificationTGFBR2/SMAD2 signallingm6A modification

Substanzen

AlkB Homolog 5, RNA DemethylaseALKBH5 protein, humanAdenosineN-methyladenosineSmad2 Protein

Autor:innen und Institutionen

  • Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, School of Basic Medical Sciences, Guangzhou Medi…
  • Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong 510515, China.
  • Department of Anesthesiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou 511436, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  • Department of Cardiology, Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Dongxing Zhu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Science and Technology Projects of Guangzhou

Zitieren

APA

Wang, Y., He, S., Lan, L., Yu, H., Zhao, H., Xie, Y., Zhong, G., Yuan, L., Li, K., Hu, X., Macrae, V. E., Fu, X., Chen, G., & Zhu, D. (2025). The N6-methyladenosine demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae253

Vancouver

Wang Y, He S, Lan L, Yu H, Zhao H, Xie Y, et al. The N6-methyladenosine demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification. Cardiovascular Research. 2025. doi:10.1093/cvr/cvae253

BibTeX
@article{Wang2025,
  author = {Wang, Yueheng and He, Shengping and Lan, Lan and Yu, Hongjiao and Zhao, Huan and Xie, Yuchen and Zhong, Guoli and Yuan, Liang and Li, Kun and Hu, Xiao and Macrae, Vicky E and Fu, Xiaodong and Chen, Guojun and Zhu, Dongxing},
  title = {The N6-methyladenosine demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvae253}
}
Kostenlos starten →